Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
145.30
+0.22 (+0.15%)
5:29:23 PM EDT: $145.56 +0.26 (+0.18%)
Earnings Announcements

Janssen Submits New Drug Application To U.S. FDA For Uptravi Injection

Published: 09/30/2020 11:34 GMT
Johnson & Johnson (JNJ) - Janssen Submits New Drug Application (nda) to U.S. FDA for Uptravi® (selexipag) Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (pah).
Janssen - Submission of NDA to FDA for Uptravi As an Injection for Intravenous (iv) Use for Treatment of Pulmonary Arterial Hypertension.
Revenue is expected to be $21.67 Billion
Adjusted EPS is expected to be $1.84

Next Quarter Revenue Guidance is expected to be $21.65 Billion
Next Quarter EPS Guidance is expected to be $2.22

More details on our Analysts Page.